NEW YORK (GenomeWeb News) – PerkinElmer today announced it has acquired Chemagen Biopolymer-Technologie as part of its strategy to advance its product offerings in the molecular diagnostics and research markets.
Financial and other terms of the deal were not disclosed.
Based in Baesweiler, Germany, Chemagen offers automated nucleic acid isolation products. Its M-PVA Magnetic Bead technology is used to purify DNA, RNA, or viral DNA/RNA, and its instrument, the Chemagic MSM, enables the automated separation of nucleic acids from sample volumes between 10 microliters and 10 milliliters.
Daniel Marshak, CSO and president of PerkinElmer's Emerging Diagnostics business, said in a statement that the addition of Chemagen's products "will provide the company with robust platforms and solutions to meet the needs of the rapidly evolving molecular diagnostics market."
He added, "Our ability to provide automated nucleic acid isolation technologies through this acquisition significantly facilitates applications such as large-scale pathogen detection in blood banking, human genetics applications such as HLA typing, autoimmune analysis, and tissue rejection analysis."